Table 1 Association between SHON protein nuclear expression and clinicopathological variables in the NUH-ES-BC cohort (n = 1,650)
Variables | SHON protein nuclear expression | χ2 p value (2 sided) | |
|---|---|---|---|
Low N (%) | High N (%) | ||
(A) Pathological parameters | |||
Lymph node (LN) metastases | 0.824 | ||
Negative | 753 (62.0) | 28 (63.6) | |
Positive | 462 (38.0) | 16 (36.4) | |
Gradea | <0.001* | ||
Low (G1) | 183 (15.1) | 17 (38.6) | |
Intermediate (G2) | 373 (30.8) | 20 (45.5) | |
High (G3) | 656 (54.1) | 7 (15.9) | |
Tumour size (cm) | 0.332 | ||
T1 a + b (≤ 1.0) | 120 (9.9) | 6 (13.6) | |
T1 c (> 1.0–2.0) | 596 (49.2) | 26 (59.1) | |
T2 (> 2.0–5.0) | 462 (38.1) | 11 (25.0) | |
T3 (> 5.0) | 34 (2.8) | 1 (2.3) | |
Mitotic index | <0.001* | ||
M1 | 370 (30.8) | 26 (61.9) | |
M2 | 231 (19.2) | 8 (19.0) | |
M3 | 600 (50.0) | 8 (19.0) | |
Pleomorphism | <0.001* | ||
P1 | 24 (2.0) | 1 (2.4) | |
P2 | 428 (35.6) | 29 (69.0) | |
P3 | 749 (62.4) | 12 (28.6) | |
Tubule formation | 0.004* | ||
T1 | 68 (5.7) | 2 (4.8) | |
T2 | 394 (32.8) | 24 (57.1) | |
T3 | 739 (61.5) | 16 (38.1) | |
Lympho-vascular invasion | 0.587 | ||
Positive | 788 (65.8) | 30 (69.8) | |
Negative | 410 (34.2) | 13 (30.2) | |
Histological type of invasive carcinoma | 0.016* | ||
Invasive ductal carcinoma - no special type | 637 (61.5) | 11 (36.7) | |
Tubular carcinoma | 210 (20.3) | 8 (26.7) | |
Medullary carcinoma | 25 (2.4) | 0 (0.0) | |
Invasive lobular carcinoma | 79 (7.6) | 5 (16.7) | |
Others | 84 (8.1) | 6 (20.0) | |
(B) Molecular characteristics | |||
ERα (IHC) | 0.044* | ||
Negative | 348 (29.1) | 6 (14.6) | |
Positive | 848 (70.9) | 35 (85.4) | |
PR (IHC) | 0.049* | ||
Negative | 507 (45.1) | 11 (28.9) | |
Positive | 617 (54.9) | 27 (71.1) | |
HER2 overexpression | 0.052 | ||
No | 1,038 (87.7) | 41 (97.6) | |
Yes | 145 (12.3) | 1 (2.4) | |
HER3 (IHC) | 0.155 | ||
Negative | 474 (49.6) | 16 (64.0) | |
Positive | 482 (50.4) | 9 (36.0) | |
HER4 (IHC) | 0.006* | ||
Negative | 401 (41.6) | 19 (67.9) | |
Positive | 563 (58.4) | 9 (32.1) | |
Androgen receptor (IHC) | 0.034* | ||
Negative | 369 (39.1) | 4 (17.4) | |
Positive | 574 (60.9) | 19 (82.6) | |
EGFR (IHC) | 0.974 | ||
Low | 746 (79.7) | 16 (80.0) | |
High | 190 (20.3) | 4 (20.0) | |
MIB1 (Ki67) (IHC) | 0.001* | ||
Low | 325 (32.4) | 20 (58.8) | |
High | 679 (67.6) | 14 (41.2) | |
BRCA1 (IHC) | 0.102 | ||
Absent | 174 (20.4) | 1 (5.3) | |
Normal | 677 (79.6) | 18 (94.7) | |
SPAG5 (IHC) | 0.093 | ||
Low | 696 (78.7) | 24 (92.3) | |
High | 188 (21.3) | 2 (7.7) | |
KIF2C (IHC) | <0.001* | ||
Low | 264 (32.5) | 17 (68.0) | |
High | 549 (67.5) | 8 (32.0) | |
PARP1 (IHC) | 0.012* | ||
Low | 537 (73.5) | 9 (47.4) | |
High | 194 (26.5) | 10 (52.6) | |
TOPO2A (IHC) | 0.001* | ||
Low | 398 (46.7) | 3 (12.0) | |
High | 454 (53.3) | 22 (88.0) | |
P53 (IHC) | 0.306 | ||
Low | 754 (78.1) | 20 (87.0) | |
High | 212 (21.9) | 3 (13.0) | |
P27 (IHC) | 0.057 | ||
Low | 444 (61.1) | 9 (40.9) | |
High | 283 (38.9) | 13 (59.1) | |
Cyclin B2 (IHC) | <0.001* | ||
Low | 532 (44.2) | 31 (72.1) | |
High | 671 (55.8) | 12 (27.9) | |
MDM2 (IHC) | 0.402 | ||
Low | 628 (75.3) | 12 (66.7) | |
High | 206 (24.7) | 6 (33.3) | |
MDM4 (IHC) | 0.017* | ||
Low | 667 (62.9) | 14 (42.4) | |
High | 393 (37.1) | 19 (57.6) | |
P21 (IHC) | 0.312 | ||
Negative | 474 (55.6) | 14 (66.7) | |
Positive | 379 (44.4 | 7 (33.3) | |
P16 (IHC) | 0.745 | ||
Low | 686 (84.4) | 18 (81.8) | |
High | 127 (15.6) | 4 (18.2) | |
P63 (IHC) | 0.438 | ||
Negative | 978 (97.9) | 28 (100.0) | |
Positive | 21 (2.1) | 0 (0.0) | |
CDK1 (IHC) | 0.039* | ||
Low | 506 (70.0) | 10 (100) | |
High | 217 (30.0) | 0 (0.0) | |
BCL-2 (IHC) | 0.044* | ||
Low | 385 (36.0) | 6 (18.8) | |
High | 683 (64.0) | 26 (81.3) | |
BAX (IHC) | 0.451 | ||
Low | 465 (69.6) | 13 (61.9) | |
High | 203 (30.4) | 8 (38.1) | |
CK18 (IHC) | 0.663 | ||
Negative | 108 (11.6) | 2 (8.7) | |
Positive | 820 (88.4) | 21 (91.3) | |
CK19 (IHC) | 0.192 | ||
Negative | 62 (6.2) | 0 (0.0) | |
Positive | 644 (93.8) | 26 (100.0) | |
CK14 (IHC) | 0.012* | ||
Negative | 875 (87.1) | 19 (70.4) | |
Positive | 130 (12.9) | 8 (29.6) | |
CK6 (IHC) | 0.096 | ||
Negative | 838 (82.7) | 19 (70.4) | |
Positive | 175 (17.3) | 8 (29.6) | |
SMA (IHC) | 0.991 | ||
Negative | 846 (85.1) | 23 (85.2) | |
Positive | 148 (14.9) | 4 (14.8) | |
ERCC1 (IHC) | 0.007* | ||
Low | 344 (61.2) | 4 (26.7) | |
High | 218 (38.8 | 11 (73.3) | |
TDK (IHC) | 0.948 | ||
Low | 461 (59.4) | 18 (60.0) | |
High | 315 (40.6) | 12 (40.0) | |
RECQL4 cytoplasm (IHC) | 0.137 | ||
Low | 122 (15.2) | 7 (25.9) | |
High | 673 (84.7) | 20 (74.1) | |
RECQL4 nuclear (IHC) | 0.003* | ||
Low | 405 (50.9) | 6 (22.2) | |
High | 390 (49.1) | 21 (77.8) | |
RECQL5 (IHC) | 0.027* | ||
Low | 429 (47.9) | 9 (28.1) | |
High | 466 (52.1) | 23 (71.9) | |
Vimentin (IHC) | 0.686 | ||
Low | 920 (88.6) | 25 (86.2) | |
High | 118 (11.4) | 4 (13.8) | |
E-cadherin (IHC) | 0.747 | ||
Negative | 54 (5.5) | 1 (4.0) | |
Positive | 931 (94.5) | 24 (96.0) | |
BLM cytoplasm (IHC) | 0.533 | ||
Low | 418 (45.0) | 20 (50.0) | |
High | 511 (55.0) | 20 (50.0) | |
BLM nuclear (IHC) | 0.001* | ||
Low | 518 (55.8) | 12 (30.0) | |
High | 411 (44.2) | 28 (70.0) | |
CHK1 (IHC) | 0.016* | ||
Low | 504 (52.5) | 7 (28.0) | |
High | 456 (47.5) | 18 (72.0) | |
ATM cytoplasm (IHC) | 0.311 | ||
Low | 392 (53.2) | 6 (40.0) | |
High | 345 (46.8) | 9 (60.0) | |
ATR (IHC) | 0.098 | ||
Low | 623 (64.4) | 28 (77.8) | |
High | 345 (35.6) | 8 (22.2) | |
CHK2 (IHC) | 0.039* | ||
Low | 389 (48.3) | 5 (25.0) | |
High | 416 (51.7) | 15 (75.0) | |
Phosphorylated CHK1 nuclear (IHC) | <0.001* | ||
Low | 975 (85.9 | 17 (38.6) | |
High | 160 (14.1 | 27 (61.4) | |
Phosphorylated CHK1 cytoplasm (IHC) | 0.328 | ||
Low | 359 (31.6) | 17 (38.6) | |
High | 776 (68.4) | 27 (61.4) | |
XRCC1 (IHC) | 0.122 | ||
Low | 142 (16.3) | 1 (4.3) | |
High | 728 (83.7) | 22 (95.7) | |
DNA polymerase beta (IHC) | 0.036* | ||
Low | 396 (39.3) | 7 (21.2) | |
High | 611 (60.7) | 26 (78.8) | |
DNA PK (IHC) | 0.511 | ||
Low | 317 (35.8) | 8 (29.6) | |
High | 569 (64.2) | 19 (70.4) | |
SMUG1 (IHC) | 0.063 | ||
Low | 316 (40.7) | 4 (20.0) | |
High | 461 (59.3) | 16 (80.0) | |
APE1 (IHC) | 0.008* | ||
Low | 493 (52.1) | 9 (28.1) | |
High | 454 (47.9) | 23 (71.9) | |
FEN1 (IHC) | <0.001* | ||
Low | 606 (74.1) | 8 (36.4) | |
High | 212 (25.9) | 14 (63.6) | |
Phosphorylated c-Jun (IHC) | 0.023* | ||
Low | 439 (46.7) | 7 (25.0) | |
High | 501 (53.3) | 21 (75.0) | |
Phosphorylated JNK (IHC) | 0.001* | ||
Low | 661 (72.2) | 9 (39.1) | |
High | 255 (27.8) | 14 (60.9) | |
Phosphorylated p38 (IHC) | 0.062 | ||
Low | 741 (84.1) | 16 (69.6) | |
High | 140 (15.9) | 7 (30.4) | |
SRC3 (IHC) | 0.603 | ||
Low | 541 (57.2) | 15 (62.5) | |
High | 405 (42.8) | 9 (37.5) | |
S543 (IHC) | 0.001* | ||
Low | 727 (82.9) | 12 (54.5) | |
High | 150 (17.1) | 10 (45.5) | |
ATF2 (IHC) | 0.786 | ||
Low | 455 (49.2) | 13 (52.0) | |
High | 469 (50.8) | 12 (48.0) | |
T24 (IHC) | 0.669 | ||
Low | 612 (74.6) | 15 (78.9) | |
High | 208 (25.4) | 4 (21.1) | |
T71 (IHC) | 0.252 | ||
Low | 502 (50.6) | 12 (40.0) | |
High | 490 (49.4) | 18 (60.0) | |
HAGE (IHC) | 0.476 | ||
Negative | 982 (90.8) | 33 (94.3) | |
Positive | 100 (9.2) | 2 (5.7) | |
TROAP (IHC) | 0.455 | ||
Negative | 431 (55.7) | 11 (47.8) | |
Positive | 343 (44.3) | 12 (52.2) | |
Breast cancer sub-groups | 0.001* | ||
Luminal A | 348 (34.5) | 24 (72.7) | |
Luminal B (Ki67 ≥15) | 314 (31.1) | 4 (12.1) | |
Luminal B (HER2+) | 63 (6.2) | 0 (0.0) | |
Non-luminal HER2+ | 81 (8.0) | 1 (3.0) | |
Basal-like | 155 (15.4) | 4 (12.1) | |
ERα−/HER2− none basal | 48 (4.8) | 0 (0.0) | |
Basal-like phenotype | 0.508 | ||
No | 981 (86.4) | 36 (90.0) | |
Yes | 155 (13.6) | 4 (10.0) | |
Triple negative phenotype | 0.105 | ||
No | 937 (79.5) | 36 (90.0) | |
Yes | 241 (20.5) | 4 (10.0) | |
